Scarica l'app Stockscreener
7.54
4.00%
0.29
Dopo l'orario di chiusura:
7.54
Precedente Chiudi:
$7.25
Aprire:
$7.42
Volume 24 ore:
57,989
Relative Volume:
3.13
Capitalizzazione di mercato:
$30.52M
Reddito:
$7.44M
Utile/perdita netta:
$-56.57M
Rapporto P/E:
0.2745
EPS:
27.467
Flusso di cassa netto:
$-21.40M
1 W Prestazione:
-0.13%
1M Prestazione:
+12.37%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$7.3721
$7.82
Intervallo di 1 settimana:
$7.25
$7.82
Portata 52W:
$6.32
$9.58
Kyntra Bio Inc Stock (KYNB) Company Profile
Nome
Kyntra Bio Inc
Settore
Industria
Telefono
415-978-1200
Indirizzo
350 BAY STREET, SAN FRANCISCO
Compare KYNB vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KYNB
Kyntra Bio Inc
|
7.54 | 29.35M | 7.44M | -56.57M | -21.40M | 27.47 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kyntra Bio Inc Stock (KYNB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-26 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-26 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | Downgrade | Stifel | Buy → Hold |
| 2023-06-26 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | Aggiornamento | Stifel | Hold → Buy |
| 2023-01-31 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-09-22 | Downgrade | Goldman | Neutral → Sell |
| 2021-08-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-07-16 | Downgrade | Stifel | Buy → Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | Downgrade | Mizuho | Buy → Neutral |
| 2021-03-31 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-03-02 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-01 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-26 | Iniziato | Raymond James | Underperform |
| 2020-07-10 | Ripresa | Stifel | Buy |
Mostra tutto
Kyntra Bio Inc Borsa (KYNB) Ultime notizie
KYNB Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
Oppenheimer initiates Kyntra Bio stock coverage with outperform rating - Investing.com UK
Oppenheimer initiates Kyntra Bio stock coverage with outperform rating By Investing.com - Investing.com Canada
Enterprise value to revenue forward of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Enterprise value to EBITDA forward of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Price to earnings forward of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Price to book forward of Kyntra Bio, Inc. – NASDAQ:KYNB - TradingView
KYNB Forecast — Price Target — Prediction for 2027 - TradingView
0IL8 Forecast — Price Target — Prediction for 2027 - TradingView
Kyntra Bio, Inc. Actuals & Estimates (NASDAQ:KYNB) - TradingView
Enterprise value to EBIT forward of Kyntra Bio, Inc. – NASDAQ:KYNB - TradingView
Price to book forward of Kyntra Bio, Inc. – TRADEGATE:1FG0 - TradingView
1FG0 Forecast — Price Target — Prediction for 2027 - TradingView
Kyntra Bio Inc. (KYNB) Edges Higher on Above-Average Volume, Tests Key Resistance ZoneETH Profile - dars.gov.et
Kyntra Bio, Inc. Statistics – DUS:1FG0 - TradingView
Basic earnings per share (basic EPS) of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Net debt of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Price to earnings ratio of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
KYNTRA BIO (KYNB) director awarded 7,000 stock options at $7.13 strike - Stock Titan
KYNTRA BIO (KYNB) director Ho Maykin awarded 7,000 stock options at $7.13 - Stock Titan
Kyntra Bio (KYNB) director receives 7,000 options at $7.13 strike - Stock Titan
Kyntra Bio (KYNB) awards 7,000 stock options to director - Stock Titan
Kyntra Bio shareholders elect director and approve executive pay at annual meeting - Investing.com South Africa
Kyntra Bio, Inc. 8-K SEC Filing Details June 12, 2026 – Company Information, Address, and Stock Listing - Minichart
Kyntra Bio Shareholders Back Board, Pay and Auditor - TipRanks
Kyntra Bio (NASDAQ: KYNB) investors back board, pay and PwC auditor - Stock Titan
Kyntra Bio Inc. Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineLong-Term Guidance - newsline.com
Kyntra Bio Inc. Q1 2026 Earnings: Pre‑Revenue Biotech Posts Wider‑Than‑Expected Loss, Stock Gains 5.47% - newsline.com
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: EPS Misses Expectations, Shares Rally on Pipeline Progress - newsline.com
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Wider-than-Expected Loss Despite Positive Stock ReactionShort-Term Outlook - newsline.com
Kyntra Bio stock rises on roxadustat MDS trial data - Investing.com
Kyntra Bio (KYNB) Reveals Positive Trial Results for Anemia Trea - GuruFocus
Kyntra Bio stock rises on roxadustat MDS trial data By Investing.com - Investing.com Australia
Kyntra Bio presents roxadustat data for anemia in LR-MDS patients By Investing.com - Investing.com Australia
Kyntra Bio Presents New Roxadustat Data On Improvements In Patients With Anemia Due To Lower-Risk Myelodysplastic Syndromes - TradingView
Kyntra Bio presents roxadustat data for anemia in LR-MDS patients - Investing.com
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes - The Manila Times
Kyntra Bio Presents New Roxadustat Data on Improvements in - GlobeNewswire
Kyntra Bio Receives Final $4 Million Payment Under 2025 Share Purchase Deal With AstraZeneca - Moomoo
Kyntra Bio Receives Final Payment for China Divestiture - TipRanks
Kyntra Bio (KYNB) CEO updates holdings after RSU tax-withholding event - Stock Titan
[Form 4] KYNTRA BIO, INC. Insider Trading Activity - Stock Titan
Kyntra Bio receives final $4.0M holdback from AstraZeneca, completes China sale proceeds - TradingView
Kyntra Bio (NASDAQ: FGEN) completes $220M China sale payments - Stock Titan
KYNB Initiated by Rodman & Renshaw -- Rating Set to Buy - GuruFocus
Rodman & Renshaw initiates Kyntra Bio stock with buy rating By Investing.com - Investing.com Nigeria
Rodman & Renshaw initiates Kyntra Bio stock with buy rating - Investing.com
Kyntra Bio Inc. (KYNB) Faces Selling Pressure as Stock Dips 1.47% – Key Levels in FocusFloat Adjusted Cap - newsline.com
KYNB Technical Analysis | Trend, Signals & Chart Patterns | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
Kyntra Bio Inc. Q1 2026 Earnings: EPS Miss Amid Ongoing Pre-Revenue Development PhaseEarnings Manipulation Risk - newsline.com
Kyntra Bio Inc. Q1 2026 Earnings: Wider-Than-Expected Loss Reinforces Pre-Revenue ChallengesHigh Growth Earnings - The Legal Advocate
Kyntra Bio Inc Azioni (KYNB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Kyntra Bio Inc Azioni (KYNB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Nov 13 '25 |
Buy |
9.18 |
1,000 |
9,180 |
22,239 |
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):